Head & Neck Cancer
Phase III Randomized, Placebo-Controlled Trial of Docetaxel versus Docetaxel plus ZD1839 in PS2 Patients or Previously-Treated Patients with Recurrent or Metastatic Head and Neck Cancer [ECOG 1302]
Principal Investigator:
Renee Jacobs, M.D.
Adventist La Grange Hospital
(708) 579-3418
Contact: Terri Crestani, MPH
A Phase II Study to Measure Response Rate and Toxicity of Neo-Adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional 5-Fluorouracil (5-FU) plus Cetuximab followed by Post-Operative Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of the Esophagus
Principal Investigator:
Elyse Schneiderman, MD
Contact: Jan Wilson, RN
630-634-1790